Q-omics provides the consensus-scored IGLV3-22 profile across patient tissues and cancer cell-line models. IGLV3-22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLV3-22 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, IGLV3-22 RNA expression shows 6,243 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and LUAD as cancer lineages where IGLV3-22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV3-22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV3-22 survival associations across molecular data types. IGLV3-22 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV3-22 RNA expression–survival associations across cancer types. High IGLV3-22 expression shows unfavorable associations in KICH, KIRC and ACC, but favorable associations in HNSC, SKCM and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLV3-22 RNA expression.
This table summarizes IGLV3-22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in READ for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGLV3-22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV3-22 shows lower tumor expression in READ and STAD and higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher IGLV3-22 RNA expression in tumor versus normal tissue (log2 FC = +0.566, t-test p = .040).
This table shows molecular features associated with IGLV3-22 in patient tissues and cancer cell lines. In patient samples, IGLV3-22 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
